antirna
viru
activ
polyoxometal
pom
review
special
emphasi
antirespiratori
viru
activ
mani
caus
agent
acut
viral
respiratori
infect
rather
difficult
identifi
relev
agent
given
case
rapid
clinic
mean
acut
progress
infect
definit
diagnosi
obtain
physician
need
prescrib
certain
broad
spectrum
antivir
drug
titanium
contain
polyoxotungst
exhibit
potent
antiinfluenza
viru
fluv
antirespiratori
syncyti
viru
rsv
activ
vitro
therapeut
effect
fluv
infect
mice
aerosol
inhal
proven
vanadium
substitut
polyoxotungst
antivir
activ
fluv
rsv
parainfluenza
viru
pfluv
type
dengu
fiver
viru
sar
coronaviru
vitro
thu
pom
proven
broad
spectrum
nontox
antirna
viru
agent
vitro
vivo
experi
promis
candid
firstlin
therapeut
acut
respiratori
diseas
polyoxometal
pom
neg
charg
cluster
inorgan
substanc
princip
compris
oxid
anion
earli
transitionmet
cation
shown
exhibit
antivir
activ
sever
rna
virus
includ
orthomyxovirus
paramyxovirus
flavivirus
coronavirus
retrovirus
vitro
vivo
speci
orthomyxovirus
paramyxovirus
coronavirus
caus
agent
respiratori
infect
activ
target
broad
spectrum
antivir
agent
examin
sever
type
pom
antirna
viru
activ
found
inde
broad
antivir
activ
rna
virus
caus
acut
respiratori
infect
examin
antivir
activ
myxovirus
necessari
make
cellular
viral
infect
rate
effici
sinc
usual
cytopath
effect
cpe
virus
weak
allow
colorimetr
method
evalu
inhibitori
activ
compound
viru
infect
first
appropri
tissu
cultur
cell
viru
infect
select
influenza
viru
fluv
respiratori
syncyti
viru
rsv
mdck
cell
cell
use
worker
field
cell
show
rel
clear
cpe
viral
infect
easi
detect
differ
treat
mock
treat
cell
calorimetr
mtt
method
howev
infect
paramyxoviru
parainfluenza
viru
pfluv
type
mump
viru
mpsv
measl
viru
mlsv
canin
distemp
viru
cdv
host
cell
need
select
sever
round
test
hmv
cell
origin
human
melanoma
cell
mpsv
cell
human
lymphoid
cell
mlsv
select
sinc
cell
grow
http
franceelseviercomdirectbiopha
biomedicin
pharmacotherapi
cultur
suspend
state
viru
cell
mix
well
shake
viral
infect
start
yet
unknown
reason
low
speed
centrifug
mixtur
facilit
viru
infect
rate
made
mtt
method
easi
lowspe
centrifug
viru
cell
viru
infect
cell
also
employ
monolay
cell
mdck
vero
cell
also
increas
viral
infect
effici
sometim
plaqu
reduct
method
employ
assay
rsv
mslv
cdv
use
hela
cell
rsv
tabl
polyoxotungst
exhibit
potent
inhibitori
effect
fluva
rsva
b
mlsv
without
evid
relationship
particular
cluster
form
among
exhibit
broad
spectrum
antimyxoviru
activ
select
indic
si
fluva
rsva
mlsv
respect
exceed
ribavirin
viru
order
explor
antivir
mechan
action
fluva
rsv
compound
ad
host
cell
mdck
cell
fluv
hela
cell
rsv
viru
infect
treatment
cell
extens
wash
mainten
medium
ms
chang
ms
maintain
throughout
experi
ec
viru
determin
mtt
method
fluv
plaqu
reduct
method
rsv
shown
tabl
compound
ad
virusinfect
cultur
hour
viru
inocul
maintain
throughout
experi
inhibitori
fluv
rsv
ad
cultur
adsorpt
stage
hour
hour
viru
inocul
inhibitori
rsv
fluv
compound
ad
adsorpt
penetr
maintain
throughout
experi
hour
viru
inocul
inhibitori
virus
respect
tabl
result
make
evid
obvious
inhibit
adsorpt
rsv
fluv
howev
certain
addit
inhibitori
effect
compound
infect
process
occur
viral
adsorpt
virus
although
ec
valu
assay
compound
ad
viru
adsorpt
three
six
time
higher
assay
compound
ad
point
progress
viral
infect
fact
anoth
experi
inhibit
hemolysi
chicken
erythrocyt
fusion
viru
envelop
cellular
membran
fluv
data
shown
syncytium
format
fusion
viru
infect
cell
uninfect
cell
rsv
fig
tabl
describ
polyoxotungst
inhibit
bind
fluv
cellular
membran
probabl
antivir
effect
occur
later
step
viru
replic
examin
polyoxotungst
contain
titanium
heteromet
ion
k
h
ge
ti
valu
fluv
si
respect
examin
fax
scan
fac
analysi
viru
bound
mdck
cell
inhibit
compound
found
inhibit
bind
fluv
cell
fig
see
legend
figur
experiment
procedur
penetr
envelop
virus
wide
report
start
fusion
viral
envelop
cellular
membran
fusion
fluv
envelop
cellular
membran
occur
acid
condit
endosom
virion
envelop
label
compactli
fluoresc
molecul
ie
octadecyl
rhodamin
b
chlorid
fluoresc
quench
detect
fluoromet
contact
viral
envelop
cell
membran
membran
fusion
taken
place
viral
protein
molecul
label
fluoresc
move
cell
membran
result
densiti
molecul
decreas
fluoresc
recov
dequench
fig
order
analyz
inhibit
fusion
viru
envelop
cell
membran
fluoresc
dequench
test
perform
use
rhodaminelabel
viru
particl
mdck
cell
interact
fluoresceinlabel
viru
cell
membran
fluresc
increas
gradual
factor
contact
period
titanium
contain
polyoxotungst
ad
contact
viru
cell
membran
dequench
fluoresc
fuse
membran
remark
reduc
compar
untreat
membran
contact
viru
period
fig
inhibit
observ
fusion
two
differ
subtyp
fluv
fluv
b
sendai
viru
pfluv
type
data
shown
thu
inhibitori
activ
shown
specif
fluv
select
resist
fluv
strain
sever
passag
fluv
mdck
cell
presenc
effect
dose
rc
resist
pm
ec
time
higher
parent
strain
amino
acid
substitut
protein
parent
mutant
strain
analyz
substitut
asparagin
threonin
respect
tabl
locat
head
posit
posit
interfac
trimer
probabl
inhibit
open
head
conform
chang
ha
molecul
occur
fig
thu
mechan
antifluv
activ
shown
inhibit
membran
fusion
howev
mechan
depend
natur
structur
particular
pom
anoth
pom
inhibit
bind
fluv
mdck
cell
antivir
activ
reveal
inhibit
fusion
viral
envelop
cell
membran
may
synergist
antivir
activ
fluv
replic
use
combin
compound
differ
antivir
target
ribavirin
wellknown
antivir
compound
inhibit
inocin
monophosph
dehydrogenas
activ
cell
decreas
guanosin
monophosph
pool
suppress
viral
rva
synthesi
examin
antifluv
activ
sever
differ
ratio
combin
ribavirin
vitro
compar
individu
respect
compound
term
effect
dose
sever
paramet
inhibit
mdck
cell
infect
fluv
two
fold
serial
dilut
mm
stock
dilut
ribavirin
combin
checkerboard
cross
grid
median
effect
dose
dose
ec
ec
ec
etc
determin
mtt
method
alon
ribavirin
alon
sever
differ
ratio
combin
compound
predict
percent
inhibit
valu
deriv
theoret
doserespons
curv
gener
individu
doserespons
data
riba
virin
combin
index
ci
calcul
equat
ci
indic
fraction
dose
combin
compound
respect
requir
median
effect
inhibitori
effect
dose
compound
respect
requir
produc
median
effect
inhibitori
effect
compound
use
alon
case
ribavirin
compound
mutual
nonexclus
drug
term
mechan
action
ci
synerg
indic
ci
indic
effect
addit
ci
antagon
indic
combin
effect
examin
combin
ribavirin
shown
fig
ci
valu
alway
less
fraction
affect
determin
ec
ec
cytotox
ribavirin
combin
examin
trypan
blue
exclus
method
shown
tabl
combin
ribavirin
exhibit
slightli
increas
cytotox
compar
compound
use
individu
howev
combin
increas
cytotox
potent
inhibit
cell
viabil
obtain
combin
ribavirin
exhibit
synergist
therapeut
effect
mice
infect
fluv
one
hundr
percent
control
mice
infect
ld
fluv
treat
compound
die
day
follow
infect
infect
mice
treat
aerosol
ribavirin
either
singli
combin
everi
hour
day
compound
prepar
pb
ph
concentr
mm
mm
ribavirin
infect
mice
place
chamber
separ
expos
compound
use
continu
aerosol
gener
experi
dose
compound
given
mice
express
term
concentr
compound
stock
solut
day
control
untreat
mice
die
half
mice
treat
mm
mm
ribavirin
surviv
ec
ribavirin
day
infect
calcul
mm
respect
mm
ec
mm
ribavirin
ec
combin
use
treat
infect
mice
mice
surviv
day
follow
infect
end
experi
day
infect
indic
fig
surviv
found
infect
mice
group
combin
mm
mm
ribavirin
mm
ribabirin
alon
mm
alon
use
thu
surviv
rate
mice
treat
combin
ribavirin
ratio
significantli
higher
mice
group
receiv
singl
treatment
twice
dose
mm
ribavirin
mm
throughout
experi
fig
lung
infect
untreat
mice
mice
treat
mm
mm
ribavirin
alon
becam
swollen
redden
due
congest
hand
lung
infect
mice
treat
combin
mm
mm
ribavirin
remain
normal
grayish
white
congest
data
shown
viral
titer
lung
infect
mice
determin
four
group
mice
everi
hour
infect
shown
fig
viral
titer
infect
mous
lung
increas
tcid
g
hor
follow
infect
decreas
tcid
g
hour
respect
viral
titer
lung
infect
mice
treat
combin
mm
ribavirin
mm
consist
lower
lung
control
mice
treat
compound
individu
fig
sever
worker
report
anti
rna
viru
pom
activ
ikeda
et
al
report
broad
spectrum
antivir
activ
includ
activ
orthoand
paramyxovirus
herpesvirus
retrovirus
compound
previous
report
broad
spectrum
antimyxoviru
activ
tabl
barnard
et
al
report
antirsv
activ
sever
polyoxotungst
among
certain
germaniumor
zirconiumcontain
polyoxotungst
respect
exhibit
potent
select
antirsv
activ
doubl
keggin
structur
barrel
structur
comment
silicon
germanium
niobium
center
doubl
keggin
structur
yield
antivir
activ
huffman
et
al
also
report
antifluv
fluv
b
activ
germanium
silicon
contain
polyoxotungst
singl
especi
germanium
contain
doubl
keggintyp
polyoxotungst
potent
select
antifluv
compound
liu
et
al
chines
chemist
group
synthes
heteropoli
blue
keggintyp
polyoxotungst
ce
h
bw
mn
h
compound
design
exhibit
potent
therapeut
effect
fluv
infect
mice
given
either
oral
intraperiton
report
prompt
us
identifi
broad
spectrum
antirna
viru
pom
use
therapi
acut
viral
respiratori
infect
examin
seven
titanium
vanadium
substitut
polyoxotungst
keggin
keggin
compound
exhibit
broad
spectrum
antirna
viru
activ
except
antivir
activ
pfluv
cdv
dfv
respect
compound
demonstr
potent
antihiv
activ
among
two
vanadiumsubstitut
doubl
keggin
polyoxotungst
exhibit
particularli
potent
select
antihiv
activ
vitro
tabl
antihiv
activ
examin
magi
test
use
hela
cell
ec
compound
nm
select
indic
exceed
respect
show
antihiv
activ
earli
stage
infect
probabl
adsorpt
stage
also
inhibit
syncytium
format
cell
uninfect
cell
cell
infect
cell
order
analyz
target
molecul
interact
adsorptionpenetr
process
examin
inhibitori
effect
bind
mous
antibodi
monoclon
polyclon
target
molecul
inhibit
bind
antibodi
inhibit
bind
antibodi
target
molecul
probabl
inhibitori
interact
receptor
bind
site
similar
result
pom
antihiv
mechan
action
report
witvrouw
et
al
use
dowson
doubl
dawson
structur
polyoxotungst
howev
suggest
also
block
bind
molecul
cover
receptor
site
compound
sever
acut
respiratori
syndrom
sar
first
emerg
late
guangdong
provinc
southern
china
spread
neighbor
countri
eventu
around
world
eight
thousand
peopl
judg
probabl
case
infect
patient
lost
coronavirus
wide
distribut
among
avian
mammalian
speci
commonli
caus
infect
replic
cycl
coronaviru
permiss
cell
common
adsorpt
cellular
membran
receptor
ntermin
portion
viral
spike
glycoprotein
envelop
use
sinc
pom
proven
inhibit
adsorpt
sever
envelop
rna
virus
examin
nine
titanium
vanadium
contain
polyoxotungst
one
heteropolyoxometal
tungsten
substitut
niobium
tabl
three
coronavirus
shown
pathogen
mammal
use
virus
transmiss
gastroenter
viru
swine
tgev
felin
infecti
periton
viru
fipv
sar
coronaviru
sarsv
respect
shown
tabl
pom
exhibit
antitgev
activ
sarsv
vanadiumsubstitut
keggin
sandwich
type
pom
display
activ
fipv
appar
relationship
structur
antivir
activ
vanadiumsubstitut
keggin
sandwich
type
polyoxotungst
exert
potent
select
anticoronaviru
activ
tabl
previous
report
possess
broad
spectrum
antirna
viru
activ
includ
activ
fluv
rsv
pfluv
compound
also
display
potent
select
antisarsv
activ
vitro
although
yet
report
pom
clinic
use
vitro
vivo
experi
shown
compound
potent
broad
spectrum
term
antivir
activ
acut
respiratori
diseas
virus
sinc
clinic
diagnosi
respiratori
viru
infect
difficult
laboratori
confirm
excess
time
consum
broad
spectrum
antivir
compound
ribavirin
interferon
pom
promis
initi
treatment
undetermin
respiratori
viral
diseas
work
elucid
drug
combin
drug
ad
clinic
pharmacopeia
